BioMarin Pharmaceutical Inc.
BMRN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $12,490,475 | $18,110,954 | $19,173,178 | $16,154,974 |
| - Cash | $942,842 | $755,127 | $724,531 | $587,276 |
| + Debt | $633,969 | $1,095,751 | $1,093,394 | $1,089,541 |
| Enterprise Value | $12,181,602 | $18,451,578 | $19,542,041 | $16,657,239 |
| Revenue | $2,853,915 | $2,419,226 | $2,096,039 | $1,846,275 |
| % Growth | 18% | 15.4% | 13.5% | – |
| Gross Profit | $2,273,680 | $1,887,164 | $1,593,016 | $1,375,760 |
| % Margin | 79.7% | 78% | 76% | 74.5% |
| EBITDA | $650,528 | $306,773 | $265,359 | $47,433 |
| % Margin | 22.8% | 12.7% | 12.7% | 2.6% |
| Net Income | $426,859 | $167,645 | $141,561 | -$64,080 |
| % Margin | 15% | 6.9% | 6.8% | -3.5% |
| EPS Diluted | 2.21 | 0.88 | 0.75 | -0.35 |
| % Growth | 151.1% | 17.3% | 314.3% | – |
| Operating Cash Flow | $572,841 | $159,259 | $175,902 | $304,536 |
| Capital Expenditures | -$97,418 | -$96,691 | -$120,959 | -$119,225 |
| Free Cash Flow | $475,423 | $62,568 | $54,943 | $185,311 |